Chair, Department of Health Services Research
Professor, Department of Breast Medical Oncology
University of Texas MD Anderson Cancer Center
On behalf of Breast International Group (BIG) and The North American Breast Cancer Groups (NABCG)
Co-Investigators: Fatima Cardoso, MD, Champalimaud Cancer Center, Lisbon, Portugal; John M.S. Bartlett, MD, The University of Edinburgh, Edinburgh, Scotland; and Peggy L. Porter,MD, Fred Hutchinson Cancer Research Center, Seattle, WA
Due to the rarity of the male breast cancer, international cooperation is necessary to undertake relevant projects with potential clinical impact. With BCRF support, the Male Breast Cancer International Registration and Biologic Characterization Program has been launched, as a joint effort between the Breast International Group (BIG) and the North American Breast Cancer Groups (NABCG) and coordinated by the European Organization for the Research and Treatment of Cancer (EORTC). In the first part of this program, clinical data and tumor samples from male BC cases treated in the last 20 years are being collected. Patients are accruing rapidly, with about 1600 patients registered, which makes this study the largest series of male breast cancer cases ever investigated. The pathology analysis of these tumor samples in the central labs has begun and will lead to a better understanding of the biological characteristics of this disease and to the identification of important potential prognostic (indicative of the good or bad outcome of the disease) and predictive (indicative of probability of response to certain therapies) markers. In 2013-2014, this international team plans to launch the second part of this program, a prospective registry, and will continue negotiations for the third part, a prospective clinical trial.
The accrual closed early September 2013 and 1,800 patients have been registered. This is the largest series of male breast cancer ever studied. The pathology analysis of these tumor samples in the central labs is ongoing and will lead to a better understanding of the biological characteristics of this disease and to the identification of important potential prognostic (indicative of the good or bad outcome of the disease) and predictive (indicative of probability of response to certain therapies) markers. A 1st presentation of these data is expected during the 9th European Breast Cancer Conference, in Glasgow, Scotland, in March 2014. The second part of this program, a prospective registry, has just been launched (first patients are expected in February 2014) and negotiations are ongoing for the third part, a prospective clinical trial.
Dr. Sharon Giordano is a Professor with tenure at the University of Texas M. D. Anderson Cancer Center in the Department of Breast Medical Oncology and Chair of the Department of Health Services Research.
Dr. Giordano received her undergraduate degree from Yale University and graduated Summa Cum Laude and With Distinction in Biology. Dr. Giordano received her M.D. degree from The Johns Hopkins School of Medicine in 1996. She is a board certified Medical Oncologist. In 2004, Dr. Giordano received a Master of Public Health degree in Disease Control from The University of Texas School of Public Health.
Dr. Giordano’s research interests include breast cancer outcomes research, late effects of treatment, and male breast cancer. She is currently funded through the American Cancer Society, CPRIT, and Komen.
Dr. Giordano is on the editorial boards for Cancer and the Journal of Clinical Oncology. Dr. Giordano has received awards including the Faculty Educator of the Month (2009), the Distinguished Alumnus Award (2010), Mentor of the Year Award (2011), Teaching Department of the Year (2011, 2013), and Faculty Scholar Award (2012). Dr. Giordano is the past Track Leader for the American Society of Clinical Oncology (ASCO) Health Services Program Committee, past member of the ASCO Education Committee, and is a current member and chair-elect of the ASCO Clinical Practice Guideline Committee. She also serves on National Comprehensive Cancer Network Breast Cancer Guideline Committee.